Sep 14, 2022 / 03:45PM GMT
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst
Hey, everyone, good morning. My name is Tejas Savant, and I'm the life science tools and diagnostics analyst at Morgan Stanley. It's my pleasure this morning to host Cytek. And from the company, we have Wenbin and Patrik. Thanks, guys, for doing this. Wenbin, maybe just to set the stage for folks not as familiar with Cytek. Can you just give us a 2-minute introduction to the company, and what is it that you'd highlight as your key accomplishments since IPO?
Questions and Answers:
Wenbin Jiang - Cytek Biosciences, Inc. - President, CEO & Chairman of the BoardSure. And I think Cytek went public last year, since then the company has continued to execute based on what we presented to the investment community to the public. Over the last 12 months, we grew our revenue consistently quarter-by-quarter. And also, one of the differentiation factor for Cytek is we operate the company based on making sure we continue to maintain the company's profitability while keep the growth momentum.
Trustpilot
